Sign up for free newsletter

 

Cells

Kurma Partners invests in OxThera

Kurma Partners’s Biofund II, the first venture capital fund dedicated to financing innovation in the rare diseases space, has made its maiden EUR7.5 million investment in Oxthera, a Stockholm-based biopharmaceutical company.

OxThera is currently conducting a placebo-controlled clinical trial with Oxabact in patients with primary hyperoxaluria at seven clinical sites in three countries.

Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death.
 
Rémi Droller, managing partner of Kurma Partners, who joins the board of directors of OxThera, says: “This first investment of Kurma Biofund II, is fully consistent with our investment strategy to support business innovation for Life Sciences in Europe, in a context where the development of new treatments and diagnostic tools for rare diseases is increasingly sought-after by industrialists seeking therapeutic innovation.”


Subscribe to free daily newsletter
MediaWatch WA awards 2015

See interviews and presentation at the Wealth Adviser 2015 awards ceremony, held at Sketch, Mayfair on the 15th May .... »

latestjobs
QA Engineer/SoftwareTest- Prop Trading Firm

Fri, 29 May 2015 00:00:00 GMT

Interest Rates Valuations

Fri, 29 May 2015 00:00:00 GMT

Senior/Lead Software Development -Bank/Hedge Funds

Fri, 29 May 2015 00:00:00 GMT

events
2 days 6 hours from now - Dubai
3 days 6 hours from now - Chicago
3 days 6 hours from now - Boston
specialreports